T. Rowe Price Investment Management
BDTX icon

T. Rowe Price Investment Management’s Black Diamond Therapeutics BDTX Stock Holding History

T. Rowe Price Investment Management’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.45M Sell
4,028,202
-6,534,901
-62% -$16M ﹤0.01% 634
2026
Q1 		$22.5M Sell
10,563,103
-43,496
-0.4% -$103K 0.02% 455
2025
Q4 		$25.8M Sell
10,606,599
-137,508
-1% -$487K 0.02% 452
2025
Q3 		$40.7M Buy
10,744,107
+231,973
+2% +$679K 0.02% 414
2025
Q2 		$26.1M Buy
10,512,134
+112,893
+1% +$218K 0.02% 470
2025
Q1 		$16.1M Sell
10,399,241
-67,480
-0.6% -$141K 0.01% 532
2024
Q4 		$22.4M Sell
10,466,721
-267,668
-2% -$767K 0.01% 503
2024
Q3 		$46.7M Buy
10,734,389
+74,659
+0.7% +$406K 0.03% 414
2024
Q2 		$49.7M Buy
10,659,730
+3,934,365
+59% +$21.1M 0.03% 389
2024
Q1 		$34.1M Buy
6,725,365
+2,797,486
+71% +$11.3M 0.02% 450
2023
Q4 		$11M Buy
3,927,879
+1,774,291
+82% +$4.16M 0.01% 509
2023
Q3 		$6.18M Buy
+2,153,588
New +$7.93M ﹤0.01% 537

Other funds holding BDTX

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

T. Rowe Price Investment Management's BDTX Position: Q2 2026 in Review

T. Rowe Price Investment Management reduced its Black Diamond Therapeutics (BDTX) stake by 62% in Q2 2026, selling an estimated $16M and leaving 4,028,202 shares worth $7.45M. The position accounts for ﹤0.01% of the portfolio, ranked #634.

T. Rowe Price Investment Management first reported a position in BDTX in Q3 2023 and has held it in 12 quarters since. The position peaked at $49.7M in Q2 2024. 96 funds tracked by Wall St. Rank hold BDTX as of Q2 2026.

  • T. Rowe Price Investment Management held 4,028,202 shares of Black Diamond Therapeutics worth $7.45M as of Q2 2026.
  • T. Rowe Price Investment Management sold 6,534,901 Black Diamond Therapeutics shares in Q2 2026, an estimated $16M.
  • Black Diamond Therapeutics made up ﹤0.01% of T. Rowe Price Investment Management's portfolio in Q2 2026, its #634 holding.
  • T. Rowe Price Investment Management first reported a position in Black Diamond Therapeutics in Q3 2023 and has held it in 12 quarters since.
  • T. Rowe Price Investment Management's Black Diamond Therapeutics position peaked at $49.7M in Q2 2024.
  • 96 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2026.

Based on T. Rowe Price Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.